Navigation Links
1st Pediatric Total Artificial Heart Patient Discharged Home Using Freedom® Portable Driver

TUCSON, Ariz., Sept. 7, 2011 /PRNewswire/ -- SynCardia Systems, Inc. (, manufacturer of the SynCardia temporary Total Artificial Heart, announced today that Texas Children's Hospital in Houston has discharged its first pediatric Total Artificial Heart patient to wait for a matching donor heart at home. On Aug. 31, 18-year-old Jordan Merecka left the hospital using the Freedom® portable driver, a wearable power supply for his Total Artificial Heart.


"Having Jordan home again is the best gift in the world," said Suzanne Merecka, Jordan's mother. "The artificial heart was a blessing when he needed it desperately and his father and I are glad that Texas Children's could offer a life-saving option when things looked very grim. He still has a heart transplant in his future, but the artificial heart has helped him grow stronger. He will be ready when the time comes."

Jordan is participating in the FDA-approved Investigational Device Exemption (IDE) clinical study of the Freedom portable driver. Weighing 13.5 pounds, the Freedom driver is the first U.S. portable driver designed to power the Total Artificial Heart both inside and outside the hospital.  

"When I get home, I hope to be able to go fishing in the ponds in my neighborhood, hang out with my friends again, just relax, sit in my favorite chair," said Jordan. "I'm going to enroll in college classes while I'm waiting at home for my transplant."

Jordan was born with multiple congenital heart defects, including his heart on the wrong side of his chest (dextrocardia) and his heart vessels backwards (corrected transposition of the great arteries). In April 2011, Jordan was admitted to the hospital after he progressed to end-stage biventricular failure while awaiting a heart transplant. In May, all of his organs began to fail and he was placed on a ventilator. To save Jordan's life, on May 22, his doctors performed the hospital's first implant of SynCardia's Total Artificial Heart.

"It was always our plan to move Jordan to the Freedom driver as soon as he was strong enough and had met all the protocol guidelines," said Dr. David L.S. Morales, pediatric cardiovascular surgeon at Texas Children's Heart Center and associate professor of surgery and pediatrics at Baylor College of Medicine (BCM), who implanted the Total Artificial Heart. "Jordan will gain a morale boost by being out of the hospital, enjoying a more active teen life as he waits for heart transplantation."

Watch news stories about Jordan
View video of The Jordan Merecka Story: Parts 1 & 2 on YouTube
Read press release from Texas Children's Hospital

CAUTION – The Freedom® portable driver is an investigational device, limited by United States law to investigational use.

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the Total is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. More than 950 implants account for more than 230 patient years of life.

Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end-stage biventricular failure. The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through both ventricles. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

In March 2011, Fast Company magazine ranked SynCardia #20 among the World's 50 Most Innovative Companies "for giving mobility to artificial heart recipients." Also in March, the longest running health and wellness series on public television, "Healthy Body, Healthy Mind," produced a 30-minute program featuring SynCardia's Total Artificial Heart. View here

For additional information, please visit:

Like SynCardia on Facebook

Follow SynCardia on Twitter – @SynCardia

Connect with SynCardia on LinkedIn

Media Contact:
Don Isaacs
Vice President of Communications
SynCardia Systems, Inc.
Cell: (520) 955-0660

SOURCE SynCardia Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States
2. Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients
3. Texas Childrens Hospital is First Pediatric Hospital in the Nation to Implant Artificial Heart
4. Pediatrics Study Finds Children Taking ADHD Medications Did Not Suffer More Serious Heart Problems or Cardiovascular-related Death
5. New Phase 3 Study Results Show REMICADE® is Effective in the Treatment of Pediatric Patients With Moderate to Severe Ulcerative Colitis
6. Virginia Tech, Carilion team with physician to create digital ER pediatric response chart
7. European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri
8. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
9. Cardon Children's Medical Center Adopts TrueVision 3D Surgical Visualization Platform for Department of Pediatric Neurosurgery
10. Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
11. Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section
Post Your Comments:
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/23/2016)... adds 2016 global ... pharmaceuticals section with historic and forecast data along ... Complete report on the Cell Culture ... companies and supported with 261 tables and figures ... The Global Cell Culture Media Industry ...
Breaking Biology Technology:
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):